No Data
No Data
NervGen Pharma Corp. Price Target Announced at C$4.00/Share by Stifel Nicolaus
NervGen Pharma Corp. Price Target Announced at C$4.00/Share by Stifel Nicolaus
NervGen Completes $23 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - NervGen Pharma Corp. (TSXV: NGEN) ("
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units
NervGen Pharma (NGEN.V) on Thursday said it is raising it is raising C$20.1 million in a bought-deal offering of share units. The biotech company said it is selling an underwriting syndicate 8.52-mill
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning underway to make NVG-291 available to placebo-treated subjects following co